Porton USA., 6 Cedarbrook Drive, Cranbury, NJ, 08512, USA.
Genentech, Inc., 4625 NE Brookwood Parkway, Hillsboro, OR, 97124, USA.
Pharm Res. 2024 Jul;41(7):1533-1541. doi: 10.1007/s11095-024-03724-z. Epub 2024 Jun 13.
Hydrates are often used as pharmaceutical active pharmaceutical ingredients (API), especially when anhydrates may not be feasible likely due to physicochemical properties concerns. Pharmaceutical hydrates, whereas water is present as crystal adduct, are feasible for drug products as they do not pose any safety concern. Hydrates can impart many different advantages; therefore, they are quite common and preferred solid forms for numerous pharmaceutical materials on market. However, hydrates may involve various phase transitions, which may impact the stability and processability of drug substance.
Phase transitions, which include temperature-induced dehydration and moisture-facilitated rehydration are investigated by different solid-state analytical techniques such as powder x-ray diffraction, thermogravimetric analysis, differential scanning calorimetry, polarized light microscopy, and single-crystal x-ray diffraction.
This research investigation focuses on the different phase transition behaviors of a newly discovered pharmaceutical compound with three channel hydrates, two of which confirmed by single-crystal analysis. The retention or rearrangement of crystal structures over the transitions are studied. Hydrate 3 exhibits a characteristic feature of channel hydrate that involves symmetric lattice relaxation. Unlike hydrate 3, hydrate 2 results in a potentially new unit cell upon dehydration due to asymmetric lattice relaxation, which converted back to Hydrate 2 in presence of water, a very unique behavior for a channel hydrate, rarely observed, which entails novelty of this research work.
The relationship among crystal forms of different hydrates of this new compound is thus established. The current investigation is a vital part of drug product risk assessment for hydrates to avoid any challenges during manufacturing operations and/or stability studies. This investigation was successfully applied in the present study and can be expanded to other newly discovered APIs in future.
水合物通常被用作药物活性药物成分(API),尤其是当无水物由于物理化学性质的问题而不可行时。药用水合物,其中水以晶体加合物的形式存在,对于药物产品是可行的,因为它们不会带来任何安全问题。水合物可以带来许多不同的优势;因此,它们是市场上许多药物材料常用且首选的固体形式。然而,水合物可能涉及各种相转变,这可能会影响药物物质的稳定性和可加工性。
通过粉末 X 射线衍射、热重分析、差示扫描量热法、偏光显微镜和单晶 X 射线衍射等不同的固态分析技术,研究包括温度诱导脱水和湿度促进再水合在内的相转变。
这项研究调查集中在一种新发现的药物化合物的三种通道水合物的不同相转变行为上,其中两种通过单晶分析得到证实。研究了转变过程中晶体结构的保留或重排。水合物 3 表现出通道水合物的特征,涉及对称晶格松弛。与水合物 3 不同,水合物 2 在脱水时由于不对称晶格松弛导致潜在的新单元胞的形成,在存在水的情况下又转化回水合物 2,这对于通道水合物来说是一种非常独特的行为,很少观察到,这使得这项研究工作具有新颖性。
因此,建立了这种新化合物不同水合物晶体形式之间的关系。目前的调查是水合物药物产品风险评估的重要组成部分,以避免在制造操作和/或稳定性研究期间出现任何挑战。本研究成功地应用于本研究,并且可以扩展到未来的其他新发现的 API。